VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a ...
Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback